157 related articles for article (PubMed ID: 20688518)
1. S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase.
Matsuno K; Takai K; Isaka Y; Unno Y; Sato M; Takikawa O; Asai A
Bioorg Med Chem Lett; 2010 Sep; 20(17):5126-9. PubMed ID: 20688518
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel kynurenine production-inhibiting benzenesulfonamide derivatives in cancer cells.
Nakano S; Takai K; Isaka Y; Takahashi S; Unno Y; Ogo N; Matsuno K; Takikawa O; Asai A
Biochem Biophys Res Commun; 2012 Mar; 419(3):556-61. PubMed ID: 22369947
[TBL] [Abstract][Full Text] [Related]
3. Cyclic analogue of S-benzylisothiourea that suppresses kynurenine production without inhibiting indoleamine 2,3-dioxygenase activity.
Fukuda M; Sasaki T; Hashimoto T; Miyachi H; Waki M; Asai A; Takikawa O; Ohno O; Matsuno K
Bioorg Med Chem Lett; 2018 Sep; 28(17):2846-2849. PubMed ID: 30055888
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors.
Huang Q; Zheng M; Yang S; Kuang C; Yu C; Yang Q
Eur J Med Chem; 2011 Nov; 46(11):5680-7. PubMed ID: 21925773
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
Yue EW; Douty B; Wayland B; Bower M; Liu X; Leffet L; Wang Q; Bowman KJ; Hansbury MJ; Liu C; Wei M; Li Y; Wynn R; Burn TC; Koblish HK; Fridman JS; Metcalf B; Scherle PA; Combs AP
J Med Chem; 2009 Dec; 52(23):7364-7. PubMed ID: 19507862
[TBL] [Abstract][Full Text] [Related]
6. Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.
Smith JR; Evans KJ; Wright A; Willows RD; Jamie JF; Griffith R
Bioorg Med Chem; 2012 Feb; 20(3):1354-63. PubMed ID: 22112538
[TBL] [Abstract][Full Text] [Related]
7. Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors.
Markwalder JA; Seitz SP; Blat Y; Elkin L; Hunt JT; Pabalan JG; Jure-Kunkel MN; Vite GD; Covello K
Bioorg Med Chem Lett; 2017 Feb; 27(3):582-585. PubMed ID: 28003141
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.
Di Pucchio T; Danese S; De Cristofaro R; Rutella S
Expert Opin Ther Pat; 2010 Feb; 20(2):229-50. PubMed ID: 20100004
[TBL] [Abstract][Full Text] [Related]
9. Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.
Dolušić E; Larrieu P; Blanc S; Sapunaric F; Norberg B; Moineaux L; Colette D; Stroobant V; Pilotte L; Colau D; Ferain T; Fraser G; Galleni M; Frère JM; Masereel B; Van den Eynde B; Wouters J; Frédérick R
Bioorg Med Chem; 2011 Feb; 19(4):1550-61. PubMed ID: 21269836
[TBL] [Abstract][Full Text] [Related]
10. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
12. Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro.
Yu CJ; Zheng MF; Kuang CX; Huang WD; Yang Q
J Alzheimers Dis; 2010; 22(1):257-66. PubMed ID: 20847417
[TBL] [Abstract][Full Text] [Related]
13. Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties.
Serra S; Moineaux L; Vancraeynest C; Masereel B; Wouters J; Pochet L; Frédérick R
Eur J Med Chem; 2014 Jul; 82():96-105. PubMed ID: 24878638
[TBL] [Abstract][Full Text] [Related]
14. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
Yang S; Li X; Hu F; Li Y; Yang Y; Yan J; Kuang C; Yang Q
J Med Chem; 2013 Nov; 56(21):8321-31. PubMed ID: 24099220
[TBL] [Abstract][Full Text] [Related]
15. A powerful yeast-based screening assay for the identification of inhibitors of indoleamine 2,3-dioxygenase.
Cerejo M; Andrade G; Roca C; Sousa J; Rodrigues C; Pinheiro R; Chatterjee S; Vieira H; Calado P
J Biomol Screen; 2012 Dec; 17(10):1362-71. PubMed ID: 22791376
[TBL] [Abstract][Full Text] [Related]
16. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Bakmiwewa SM; Fatokun AA; Tran A; Payne RJ; Hunt NH; Ball HJ
Bioorg Med Chem Lett; 2012 Dec; 22(24):7641-6. PubMed ID: 23122865
[TBL] [Abstract][Full Text] [Related]
17. Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.
John S; Thangapandian S; Sakkiah S; Lee KW
Eur J Med Chem; 2010 Sep; 45(9):4004-12. PubMed ID: 20580138
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors.
Cheng MF; Hung MS; Song JS; Lin SY; Liao FY; Wu MH; Hsiao W; Hsieh CL; Wu JS; Chao YS; Shih C; Wu SY; Ueng SH
Bioorg Med Chem Lett; 2014 Aug; 24(15):3403-6. PubMed ID: 24939758
[TBL] [Abstract][Full Text] [Related]
19. Bimodal effect of nitric oxide in the enzymatic activity of indoleamine 2,3-dioxygenase in human monocytic cells.
López AS; Alegre E; Díaz A; Mugueta C; González A
Immunol Lett; 2006 Aug; 106(2):163-71. PubMed ID: 16797727
[TBL] [Abstract][Full Text] [Related]
20. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
Macchiarulo A; Camaioni E; Nuti R; Pellicciari R
Amino Acids; 2009 Jul; 37(2):219-29. PubMed ID: 18612775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
